◀ Back to NPY6R
JAK2 — NPY6R
Text-mined interactions from Literome
Takeishi et al., J Mol Cell Cardiol 2001
(MAP Kinase Signaling System...) :
PP2 ( 1 microm )
inhibited ischemia induced Src, BMK1 and JNK activation but not
JAK2 and p38 activation
Tabet et al., J Hypertens 2005
:
Non-receptor tyrosine kinases ( NRTK ) were studied using AG490 (
JAK2 inhibitor ) and
PP2 ( Src inhibitor )
Li et al., J Biol Chem 2008
:
PP2 , a Fyn-specific inhibitor,
blocked JAK2 , STAT3, and p38 MAPK activation and significantly attenuated apoptosis induced by H ( 2 ) O ( 2 )
Wu et al., Br J Pharmacol 2009
:
Effects of tripterine were investigated on endothelial barrier function, inducible nitric oxide synthase (iNOS) expression, nicotinamide adenine dinucleotide phasphate ( NADPH ) oxidase activity, 3-nitrotyrosine formation, protein
phosphatase type 2A (PP2A) activity,
activation of extracellular regulated kinase (ERK), c-Jun terminal kinase (JNK) and
Janus kinase ( Jak2 ), and degradation of IkappaB in microvascular endothelial cells exposed to pro-inflammatory stimulus [ lipopolysaccharide (LPS) + interferon gamma (IFNgamma) ] and on vascular permeability in air pouches of mice injected with LPS + IFNgamma
Lin et al., Toxicol In Vitro 2010
(Breast Neoplasms) :
Moreover, the JAK2 inhibitor AG490 blocked JAK2, STAT3, Src, PI3K, and Akt activation, whereas both Src inhibitor
PP2 and PI3K inhibitor wortmannin did not
affect JAK2 activation